The Weekly Recap 11/21/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni announce acquisitions, secure over $174M in new funding, receive regulatory clearances, enter new partnerships, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20).

Acera Surgical

Is set to be acquired by Solventum in a deal worth up to $900M, including a $725M cash payment as well as up to $125M in contingent cash payments based on future milestones. Acera’s Restrata^Ⓡ products leverage its proprietary electrospinning technology platform to treat complex, hard-to-heal wounds in acute care settings.

CoapTech

Appointed Brad Kreger as CEO, as Co-Founder and CEO Howard Carolan steps down and transitions to an advisory role. CoapTech develops ultrasound-guided solutions for safe and efficient gastrostomy placement; its percutaneous ultrasound gastrostomy (PUG) product and associated procedure have been used in more than 1,000 patients. 

CranioSense

Named Eric Heinz as Head of Business Development, where he will build relationships with providers, health systems, investors, and strategic partners. Heinz will continue in his role at Heinz Ventures while helping advance CranioSense’s non-invasive intracranial pressure monitoring technology.

Distalmotion

Raised $150M in Series G funding to accelerate U.S. commercial adoption of its Dexter surgical robot, with a focus on ambulatory surgical centers. The company also named former Silk Road Medical and Apollo Endosurgery CEO Chas McKhann as its executive chair of the board to support commercial growth.

Dr Jay

Announced that its technology has been acquired by Spectrum.Life, expanding its reach and accelerating the next phase of its impact. Dr Jay’s CE-marked AI mental health companion has been evaluated in a randomized controlled trial and has been shown to significantly reduce anxiety and depression symptoms.

ElectraDx

Formed a strategic capital and business alliance with TAUNS Laboratories to co-develop and commercialize next-generation point-of-care diagnostics in Japan. The partnership combines ElectraDx’s rapid, lab-quality testing platform with TAUNS’s market expertise to expand access to fast, accurate, and affordable diagnostics for infectious and chronic diseases.

Fluid Biomed

Appointed medtech industry veteran John Kilcoyne as Independent Chair of the Board of Directors. His leadership adds commercial and strategic expertise as the company accelerates development of its polymer-based stent technology to treat brain aneurysms and stroke.

Hexoskin

Received FDA 510(k) clearance for its Hexoskin Medical System, a smart shirt that enables continuous, long-term ECG and respiratory monitoring. The system offers clinical-grade cardiopulmonary data collection outside the hospital and supports both chronic disease management and decentralized clinical trials.

Innotive Diagnostics

Won a £1M grant from Pathways to Antimicrobial Clinical Efficacy (PACE) to advance development of its rapid UTI point-of-care diagnostic system and InnotiveUTI test. The system and test are being developed to diagnose UTIs and provide comprehensive bacterial ID and antimicrobial susceptibility test (AST) results within 60 minutes at the point of care.

Lauxera Capital Partners

Appointed Dr. Oern Stuge as Senior Advisor, adding deep global healthcare leadership experience to the firm’s strategic team. The move reinforces Lauxera’s commitment to supporting and scaling Europe’s next generation of healthtech innovators, following a successful collaboration with Dr. Stuge on OrganOx’s $1.5B acquisition by Terumo.

Levita Magnetics

Received FDA clearance for pediatric use of its Magnetic Surgical System (MSS), enabling laparoscopic cholecystectomies in pediatric patients ages 12 and older within a BMI range of 20–34 kg/m². Cleveland Clinic Children’s performed the first U.S. pediatric procedure using MSS with Levita’s magnetic-assisted robotic surgery (MARS™) system.

Lupin Dental

Completed its first commercial installation of the Lup^Ⓡ Robotic System in India, partnering with Pharande Dental Hospital in Pune. This milestone marks a significant step in the company’s mission to revolutionize dentistry through robotic innovation and precision and sets the stage for broader adoption.

Oath Surgical

Welcomed Sandra Clarke as an advisor to support its mission of building a value-based surgical care system. The former CFO and COO of Blue Shield of California brings decades of leadership in healthcare finance, operations, and strategy to help align incentives and elevate quality across surgical delivery.

Paradromics

Received FDA IDE approval to begin the Connect-One trial, an early feasibility study for the Connexus brain-computer interface system. The trial will evaluate the communication-restoring potential of the fully implantable BCI in patients with impaired speech and limited extremity movement (upper and lower) due to severe loss of voluntary motor control.

Picard Medical

Completed the first in vivo implantations of the Emperor, the next-generation of SynCardia’s Total Artificial Heart (TAH). The company designed the Emperor as a fully implantable, driverless version of the SynCardia TAH, providing pulsatile flow without requiring a pneumatic driver. 

RapidAI

Announced FDA clearance of its AI-powered aortic management solution, Rapid Aortic. The new tool sets a benchmark for deep clinical AI in aortic patient care and is designed to transform the acute assessment and longitudinal management of aortic disease.

SpectraWAVE

Joined forces with CryoTherapeutics and CRF to launch the ICECAP study targeting high-risk non-obstructive coronary plaques. The collaboration brings together SpectraWAVE’s DeepOCT+NIRS imaging and AI-driven plaque characterization with cryotherapy and world-class cardiovascular research to pioneer a new approach in plaque stabilization.

SynchNeuro

Secured a seed-stage investment from Boomerang Ventures to advance its non-invasive, brain-based glucose monitoring technology. The company’s EEG-powered platform provides a needle-free alternative to traditional CGMs, aiming to transform cardiometabolic health management for millions living with or at risk for Type 2 diabetes.

Synova Life Sciences

Received FDA 510(k) clearance for its Synova WAVE adipose processing system. The Synova WAVE system is intended for the closed-loop processing of lipoaspirate tissue for the purpose of transferring autologous adipose tissue for aesthetic body contouring (lipofilling) in a wide range of applications.

VahatiCor

Closed an oversubscribed $23M Series B financing to accelerate development of its A-FLUX Reducer System^Ⓡ for coronary microvascular dysfunction. The self-expanding coronary sinus reducer is designed to optimize and redistribute oxygenated blood flow, supporting and enhancing perfusion to relieve angina symptoms.

Volta Medical

Launched a joint electrophysiology offering with GE HealthCare that integrates Volta’s AF-Xplorer™ II with the CardioLab™ AltiX AI.i EP recording system. The combined solution merges advanced signal clarity and AI-driven insights to streamline workflows during atrial fibrillation ablation procedures.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.